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Abstract
Background: For clinical applications, dendritic cells (DCs) need to be generated using GMP-approved reagents. In
this study, we tested the characteristics of DCs generated in two clinical grade culture media and activated by
three maturation stimuli, Poly I: C, LPS and the mixture of proinflammatory cytokines in order to identify the
optimal combination of culture media and activation stimulus for the clinical use.
Method: We tested DCs generation using two GMP-certified culture media, CellGro and RPMI+5% human AB
serum and evaluated DCs morphology, viability and capapability to mature. We tested three maturation stimuli,
PolyI:C, LPS and the mixture of proinflammatory cytokines consisting of IL-1, IL-6, TNF and prostaglandin E2. We
evaluated the capacity of activated DCs to induce antigen-specific T cells and regulatory T lymphocytes.
Results: Cell culture in CellGro resulted in a higher yield of immature DCs resulting from increased number of
adherent monocytes. DCs that were generated in CellGro and activated using Poly I:C were the most efficient in
expanding antigen-specific T cells compared to the DCs that were generated in other media and activated using
LPS or the cocktail of proinflammatory cytokines. A comparison of all tested combinations revealed that DCs that
were generated in CellGro and activated using Poly I:C induced low numbers of regulatory T cells.
Conclusion: In this study, we identified monocyte-derived DCs that were generated in CellGro and activated using
Poly I:C as the most potent clinical-grade DCs for the induction of antigen-specific T cells.
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Introduction
The aim of vaccination approaches in human cancer is
to induce tumor-specific, long-lasting immune response
that slows down the growth of tumor cells [1,2]. The
induction of tumor immunity includes: 1) the presenta-
tion of tumor antigens by dendritic cells; 2) priming and
activation of tumor antigens-specific T cells; and 3)
homing of effector T cells to the tumor site and recog-
nition of malignant cells which leads to the elimination
of the tumor [3,4]. Dendritic cells are highly specialized
APCs with unique capacity to establish and control pri-
mary immune responses [5]. DCs reside in peripheral
tissues in an immature state where they capture and
process Ag for presentation in the context of MHC
molecules. After encountering appropriate stimuli, DCs
differentiate into mature DCs, which are characterized
by decreased endocytic activity, up-regulation of major
histocompatibility complex (MHC) class I and II mole-
cules and co-stimulatory molecules (CD86, CD80), and
responsiveness to inflammatory chemokines [6]. The
next generation of DC vaccines is expected to generate
large numbers of high-avidity effector CD4 and CD8
T cells and to overcome regulatory T cells and the
immunosuppressive environment that is established by
tumors.
Circulating blood DCs are rare (they account for < 1%
of human PBMC) and are difficult to maintain in cul-
ture [7]. Although in vivo expansion of blood DCs via
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ligand and GM-CSF can be used to increase the yield of
isolated cells, most experimental and clinical studies
currently rely on the in vitro development of DC-like
cells from CD34+ progenitor cells or blood monocytes
[8-10]. Monocytes are typically cultured for 5-7 days
with GM-CSF and IL-4 to generate immature DCs that
are activated for another 1-2 days with microbial, proin-
flammatory, or T cell-derived stimuli to obtain mature
DCs with full T cell stimulatory capacity [11-14].
For clinical use, DCs must be generated using GMP-
approved reagents and number of studies have addressed
the need to generate large numbers of DCs for clinical
trials [14-18]. In this study, we tested DC generation in
two GMP-certified culture media, CellGro and RPMI+5%
human AB serum and evaluated the morphology, viability
and capacity to mature. DCs must be activated to effi-
ciently activate T cells [19]. We tested three maturation
signals that were available in GMP quality: PolyI:C, LPS
(TLR-3 or TLR-4 ligands) and the mixture of proinflam-
matory cytokines (MC) consisting of IL-1, IL-6, TNF and
prostaglandin E2 [20-23]. We evaluated the capacity of
activated DCs to induce antigen-specific T cells and regu-
latory T lymphocytes.
Materials and methods
DC generation
Study was approved by the IRB of the Charles University,
2
nd Medical School. Immature monocyte-derived DCs
were generated as previously described [12,24]. Briefly,
peripheral blood mononuclear cells (PBMCs) were
obtained from buffy coats of healthy donors after signing
an informed consent and monocytes were separated by
allowing 2 h of cell adhesion in 75-cm
2 culture flasks
(Nunc). 1 × 10
7 adherent monocytes were cultured for
5 days in culture media in the presence of GM-CSF at the
concentration of 500 IU/ml (Leukine) and 20 ng/ml of IL-
4 (PeproTech)[25]. On day 5, DCs were seeded in 24-well
plates (Nunc) at 5 × 10
5 DC/ml and activated using Poly
( I : C )( S i g m a - A l d r i c h ,S t .L o u i s ,M O )a t2 5μg/ml, LPS
(Sigma-Aldrich) at 1 μg/ml, or a cocktail of proinflamma-
tory cytokines (TNF, IL-1 and IL-6, PGE2). Immature and
mature DCs were used for further studies.
Flow cytometry
The following monoclonal antibodies (mAbs) against the
indicated molecules were used: CD80-FITC, CD83-PE,
CD86-PE-Cy5, CD14-PE-Dy590, CD8-APC (Exbio),
CD11c-PE, HLA-DR-Alexa700, IFN-g-PE, CD4-PE_Dy747
(BD Biosciences, San Jose, CA), HLA-A2 flu-MP-PE
(Beckman Coulter), and FoxP3-PE (eBioscience). The cells
were stained for 30 min at 4°C, washed twice in PBS+0.1%
BSA and analyzed using FACSAria (BD Biosciences) with
FlowJo software. DCs were gated according to their FSC
and SSC properties and as CD11c-positive cells. Appropri-
ate isotype controls and only viable DCs were included in
the analysis.
Expansion of influenza matrix peptide (MP)-specific
T lymphocytes, intracellular IFNg staining and
HLA-A2-MP tetramer staining
Immature monocyte-derived DCs were activated for 4 h
with the indicated stimuli: Poly (I:C) at 25 μg/ml, LPS at
1 μg/ml and a mixture of proinflammatory cytokines [IL-
1b (10 ng/ml), IL-6 1000 U/ml, TNF-a (10 ng/ml and
PGE2 (1 μg/ml), maturation cocktail (MC)]. Activated
DCs were pulsed with HLA-A2-restricted peptide from
influenza MP (GILGFVFTL) 10 μg/ml (Jpt peptide tech-
nologies, Berlin); PepMix PSA 10 μg/ml (Jpt peptide tech-
nologies, Berlin); PepMix CEF 10 μg/ml (Jpt peptide
technologies, Berlin). Pulsed DCs were washed and added
to 2 × 10
5 of autologous lymphocytes in RPMI+10% FCS
in U-bottom 96 well plates at a T cell:DC ratio of 10:1 for
7d a y s[ 2 6 ] .At o t a lo f2 0U / m lo fI L - 2( P e p r o T e c hE C )
were added on day 3. On day 7, the lymphocytes were res-
timulated with fresh peptide-loaded DCs and the fre-
quency of antigen-specific T cells was determined using
intracellular staining for IFNg. Brefeldin A (BioLegend)
was added to block the extracellular release of IFNg 1h
after restimulation. After an additional 4 h of incubation,
the cells were fixed using Fixation Buffer, permeabilized
with Permeabilization Buffer and stained using anti-IFNg-
PE antibody (eBioscience) and CD8-APC (Exbio). The
frequency of influenza MP-specific CD8 T cells was deter-
mined by staining with HLA-A2-MP tetramers (Beckman
Coulter).
Frequency of Tregs in the peripheral blood
FoxP3+ expression in T cells was assessed using the PE-
anti-human FoxP3+ Staining Kit (eBiosciences). Rat
IgG2a-PE (BD Biosciences) was used as an isotype control.
The samples were also simultaneously stained with CD25-
Dy647 (Miltenyi Biotec), CD4-PE-Dy747, CD3-FITC. The
cells were acquired using FACSAria (Becton Dickinson)
and analyzed using FlowJo software (Tree Star).
Statistical analysis
Data were analyzed by Man-Whitney non-parametric
test using Statistica v.7.1 software. The results were con-
sidered statistically significant when p < 0.05.
Results
The yield of generated immature DCs in tested culture
media
We first compared the characteristics of DCs differen-
tiated in the tested media from 1 × 10
7 PBMCs. Tested
media differed in the yield of monocytes after two hours
of adherence. The number of adherent monocytes was
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Page 2 of 10significantly increased when PBMCs were cultured in
CellGro medium (Figure 1A). Consequently, a signifi-
cantly higher number of immature DCs was obtained
after 5 days of culture in the presence of IL-4 and GM-
CSF. DC generation in serum-free CellGro media yielded
an average of 1,5 times more immature DCs than the cul-
ture in RPMI supplemented with 5% AB serum (Figure
1B). We did not detect any differences in cell viability
and morphology between immature DCs that were gen-
erated in CellGro and RPMI+5% AB serum (Figure 1C).
Phenotype analysis of DCs following DC maturation with
different stimuli
To investigate the capacity of immature DCs that were
generated in tested media to be activated by different
maturation stimuli, we evaluated the expression of
Figure 1 Characteristics of immature dendritic cells that were generated in different culture media. A. Morphology and density of
adherent monocytes after 2 h of adhesion in in CellGro or RPMI+5% human AB serum. B. Total number of immature DCs that were generated
from 1 × 10
7 of PBMCs in CellGro or RPMI+5% human AB serum. Each symbol represents an individual experiment, and the horizontal bar
indicates the mean value for all experiments. * P value for comparison between tested conditions, P < 0.05. C. Purity (percentage of CD11c
positive DCs) and viability (percentage of DAPI negative cells) of DCs generated in CellGro or RPMI+5% human AB serum and activated by
tested maturation stimuli.
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antigen presentation-associated MHC class II expression
(HLA-DR). As a control, immature DCs were incubated
for 24 h in the presence of IL-4 and GM-CSF. Although
the endocytic activity of activated DCs was not signifi-
cantly different (data not shown), the phenotype analysis
revealed that the tested agents induced various degrees
of maturation-associated molecule expression (Figure 2).
Exposure of DCs that were generated in various media
to maturation signals upregulated the expression of
CD80, CD83, CD86 and HLA-DR and down-regulated
CD14 expression. LPS activation did not induce pheno-
typic maturation of immature DCs that were generated
in CellGro. Treatment of immature DCs with the mix-
ture of proinflammatory cytokines led to the most promi-
nent changes in the expression of maturation-associated
molecules.
In vitro capacity of mature DCs to induce antigen-specific
T cells
Mature DCs efficiently stimulate Ag-specific T-cell
responses. We evaluated the capacity of mature DCs to
expand influenza matrix peptide-, CEF peptide mix- and
PSA peptide mix-specific T cells. Mature DCs that were
generated in various culture media were pulsed with
antigens and used for the expansion of antigen-specific
Figure 2 The phenotype of dendritic cells that were generated in CellGro or RPMI+5% human AB serum and activated for 24 h using
tested maturation stimuli. The summary of six independent experiments (A) and representative histograms (B) are shown. * P value for
comparison with immature DCs, P < 0.05. Grey histograms represent the expression of maturation-associated molecules on immature DCs.
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T cells was analyzed one week later after restimulation
with identical peptide-loaded DCs. DCs that were gener-
ated in CellGro and activated using Poly I:C were the
most efficient in expanding antigen-specific T cells com-
pared to DCs that were generated in other media and
activated using LPS or the cocktail of proinflammatory
cytokines (Figure 3). Poly I:C activated DCs generated in
CellGro also efficiently expanded antigen specific T cells
in other models tested in this study (influenza MP, CEF
peptide mix and PSA peptide mix) (Figure 3B). Among
the tested T cell populations, the highest frequency of
influenza MP- specific T cells that were detected using
HLA-A2 tetramer staining was seen in T cells that were
stimulated using Poly (I:C)-activated DCs that were gen-
erated in CellGro (Figure 4).
Capacity of activated DCs to induce regulatory T cells
In the last set of experiments, we tested the capacity of
DCs that were generated under various conditions to
induce regulatory T cells (Tregs). Tregs expanded after 7
days of DC and T cell cocultures were determined as
CD4+ CD25+ FoxP3+ T cells. DCs that were activated
using a mixture of proinflammatory cytokines induced
the expansion of high numbers of regulatory T cells that
exceeded those induced by immature DCs. Among the
different activated DC populations, Poly I:C-activated
DCs that were generated in CellGro had the lowest ratio
FoxP3+ Tregs/antigen specific T cells and thus appear to
be the most suitable cells for use in DC cancer immu-
notherapy studies (Figure 5).
Discussion
DCs have been extensively used in immunotherapy for
their properties of initiators and modulators of the
immune response [1]. In the immature state, DCs can be
easily loaded with the desired antigens. However, imma-
ture DCs do not activate the immune response. To
become efficient antigen-presenting cells, DCs must first
undergo a process of maturation [5,27]. Protocols for the
generation of large numbers of DCs for use in cancer
immunotherapy trials need to carefully consider these
characteristics of DC physiology [28-31]. Therefore, the
first step of large-scale production of DCs for clinical trials
is to generate large numbers of immature DCs for antigen
pulsing [12,14,17,18,22,32-34]. A well-defined maturation
stimulus is subsequently applied to achieve complete and
reproducible maturation [12,23,29,35,36].
Current legislation for the products of advanced cellu-
lar therapies requires the use of GMP-compliant
reagents and manufacturing units [2,37]. Many pioneer
studies with DCs in cancer immunotherapy have been
conducted with DCs that had been generated in classical
complete cell culture media, i.e., RPMI that was supple-
mented with fetal calf or bovine sera [27,38]. The use of
FBS in the current generation of DCs for cellular ther-
apy has not been approved and therefore must be
replaced by human plasma, human serum or serum-free
clinical grade media. A well-defined protocol should
reproducibly generate clinical-grade DCs with a stable
phenotype and potent T cell stimulatory capacity. With
the increasing number of clinical studies using mono-
cytes-derived DCs for cancer immunotherapy, it is
essential to provide reliable protocols to generate suffi-
cient quantities of well-characterized, highly immuno-
genic DCs according to current cGMP guidelines
[39,40]. In this study, we tested the characteristics of
DCs that were generated using GMP-certified media
(CellGro and RPMI+ 5% human AB serum), reagents
and three types of maturation stimuli that were available
in GMP quality. The aim was to identify the optimal
combination of culture conditions that generated large
numbers of clinical-grade mature monocyte-derived
DCs with the capacity to induce an antigen-specific
immune response. The culture of adherent monocytes
in CellGro media in the presence of GM-CSF and IL-4
yielded significantly more viable immature DCs com-
pared to that of adherent monocytes in RPMI+5%
human AB serum. The difference in the final yield of
immature DCs was attributed to the higher number of
adherent monocytes after 2 h of adhesion in CellGro.
The presence of serum slightly impeded the adherence
of monocytes, which may explain the lower numbers of
adherent cells in RPMI+5% human AB serum.
The maturation status of DC is crucial for adequate T
cell recruitment, activation, expansion and differentia-
tion [41,42]. Therefore, we tested the capacity of LPS,
Poly I:C and a mixture of proinflammatory cytokines
consisting of IL-1, IL-6, TNF and prostaglandin E2 to
induce full activation of DCs that were generated in the
tested clinical-grade culture media [2,21,22,43]. Among
the tested conditions, the maturation of DCs with the
mixture of proinflammatory cytokines resulted in the
highest expression of maturation-associated molecules
in CellGro and in RPMI+5% human AB serum. LPS and
Poly I:C induced comparable maturation-associated
changes in RPMI+5% human AB serum. However, LPS
was a weak inducer of DC maturation in serum-free
CellGro media most likely due to the absence of LPS-
binding protein. The ability to activate antigen-specific
T cells is critical for the clinical effect of DC-based vac-
cines [44-46]. Therefore, we used HLA-A2-restricted
influenza MP as a model antigen to test the activating
potential of generated DCs. Among all of the tested
conditions, DCs that were generated in CellGro and
activated using Poly I:C were the most efficient in
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Page 5 of 10Figure 3 The induction of antigen-specific T cells. DCs that were generated in CellGro or RPMI+5% human AB serum were activated using
the tested maturation stimuli and subsequently used as stimulators for the induction of antigen-specific T cells. The frequency of antigen-
specific T cells was analyzed using intracellular IFNg staining. A, B. Induction of HLA-A2 influenza MP-specific CD8 T cells. The summary (A) and
representative staining (B) of five independent experiments are shown. C. Induction of HLA-A2 influenza MP-, CEF peptide mix- and PSA peptide
mix-specific T cells using DCs that were generated in CellGro and activated using Poly I:C. Representative dot plots of five independent
experiments are shown.
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quency and function, which were determined by asses-
sing influenza MP tetramer staining and IFNg
production, respectively [47-49]. Poly I:C-activated DCs
that were generated in CellGro efficiently expanded T
cells that were specific for the peptide mix consisting of
influenza, CMV- and EBV-derived peptides and the PSA
peptide mix [50,51]. Furthermore, Poly I:C-activated
DCs that were produced in CellGro induced signifi-
cantly lower numbers of regulatory T cells compared to
DCs that were activated using the cytokine cocktail.
This result is in accordance with recently published data
showing that cytokine-matured DCs expand Foxp3-posi-
tive inhibitory Tregs in vitro and in vivo [52,53].
Figure 4 DCs that were generated in CellGro or RPMI+5% human AB serum were activated using the tested maturation stimuli,
pulsed with HLA-A2-restricted influenza MP and used as stimulators for the induction of antigen-specific T cells. The frequency of
antigen-specific T cells was determined by staining with HLA-A2 influenza MP tetramers. The summary (A) and representative staining (B) of five
independent experiments are shown. The frequency of HLA-A2 influenza MP-specific T cells is shown.
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Page 7 of 10Figure 5 The expansion of Tregs by DCs that were generated in CellGro or RPMI+5% human AB serum. DCs that were generated in
CellGro or RPMI+5% human AB serum were activated using the tested maturation stimuli, pulsed with HLA-A2-restricted influenza MP and used
as stimulators for the induction of antigen-specific T cells. The frequency of CD4
+CD25
+FoxP3
+ cells was analyzed after 7 days of culture. The
summary (A) and representative staining (B) of five independent experiments are shown. * P value for comparison with immature DCs, P < 0,05.
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In this study, we demonstrated that monocyte-derived
DCs that were generated in CellGro and activated using
Poly I:C potently induced antigen-specific T cells. This
protocol has been approved for clinical use by regula-
tory authorities and represents a platform for the manu-
facturing of DC-based active cancer immunotherapy in
the settings of prostate and ovarian cancer.
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